MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stake in Exelixis, Inc. (NASDAQ:EXEL)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 3.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,774 shares of the biotechnology company’s stock after selling 761 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Exelixis were worth $795,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. Coppell Advisory Solutions LLC acquired a new position in shares of Exelixis during the 4th quarter valued at $25,000. Colonial Trust Co SC raised its holdings in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 765 shares during the period. Principal Securities Inc. raised its holdings in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares during the period. Kestra Investment Management LLC acquired a new position in Exelixis during the 4th quarter worth approximately $39,000. Finally, Crowley Wealth Management Inc. acquired a new position in Exelixis during the 4th quarter worth approximately $50,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Citigroup lifted their price objective on shares of Exelixis from $45.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, May 15th. Guggenheim set a $45.00 price target on shares of Exelixis and gave the stock a “buy” rating in a research note on Thursday, May 15th. Wall Street Zen lowered shares of Exelixis from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 15th. Wells Fargo & Company reissued a “market outperform” rating on shares of Exelixis in a research report on Thursday, April 17th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $41.00 target price on shares of Exelixis in a research report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.94.

Exelixis Price Performance

Shares of EXEL opened at $42.39 on Tuesday. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $48.85. The business’s fifty day moving average price is $38.02 and its 200 day moving average price is $36.19. The stock has a market capitalization of $11.56 billion, a PE ratio of 23.95, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25.

Insider Transactions at Exelixis

In related news, Director Tomas J. Heyman sold 4,544 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $44.29, for a total transaction of $201,253.76. Following the sale, the director now owns 32,470 shares in the company, valued at $1,438,096.30. This represents a 12.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stelios Papadopoulos sold 36,508 shares of the company’s stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $44.35, for a total value of $1,619,129.80. Following the transaction, the director now directly owns 1,279,416 shares of the company’s stock, valued at $56,742,099.60. This trade represents a 2.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 459,276 shares of company stock worth $20,945,859. 2.82% of the stock is currently owned by insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.